6ix — Find Your Next Investment

Discover investor relations events, company profiles, and opportunities on 6ix. Connect with public companies and attend live investor events.

Please enable JavaScript to use all features of 6ix.com.

Oorspronkelijke tekst

Deze vertaling beoordelen

Je feedback wordt gebruikt om Google Translate te verbeteren

Latest Press Releases

Time	Headline
Just now	GreenPower Unveils Innovative Heating Solution for Type A Nano BEAST All-Electric, Purpose-Built, Zero-Emission School Bus
8m ago	Yapi ve Kredi Bankasi : Successful issuance of 500 million US$ perpetual Additional Tier 1 Capital Transaction
13m ago	Crown Castle Names Kris Hinson as Chief Commercial Officer and Mark Lennon as Chief Information Officer
18m ago	Hovnanian Enterprises Reports Fiscal 2026 Second Quarter Results
18m ago	LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit

About

13.61USD-0.15 -1.09%

Closed • Updated at 13:34 GMT+00:00

Market Cap$395.76M

Volume161.2K

Beta1.21

RSI44.93

Gross Margin92.87%

Health TechnologyPharmaceuticals: Major

Enanta Pharmaceuticals, Inc. — investor relations, events, news, and company updates on 6ix.

Latest News

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026

Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria

Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026

Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)

Community Chat

Ask AI